February 11, 2015
By Riley McDermid, BioSpace.com Breaking News Sr. Editor
Sanofi has fired around 100 employees at its Boston research and development facility, the company confirmed Wednesday morning, with most of the cuts occurring in its oncology and global R&D departments.
Bloomberg News reported that as part of the purge, Tal Zaks, head of the group, will leave, while oncology will now be wrapped into global R&D. All of the cuts are part of a larger push by Sanofi to streamline its existing pipeline while keeping an aggressive presence in the competitive cancer space.
A spokesperson confirmed the cuts and issued the following statement:
“Sanofi communicated a natural evolution of its research and development organization that will prioritize its focus and investments in exciting areas of science and medicine,” said Sanofi. There was no comment on Zaks.
Sanofi has faced an uphill battle in recent months to keep its reputation as a desirable place to work alive and well. The French drugmaker said Thursday that it will name a new chief executive in mere weeks, as it attempted to put to rest rumors that the company could not find any executives willing to take the reins after it unceremoniously ousted its previous CEO last fall.
“The announcement will be before the end of the first quarter,” Chairman Serge Weinberg, who has been acting CEO since Chris Viehbacher was fired in October, told Reuters in Paris today.
Weinberg also said that when the company announces financial results at the end of the first quarter, Sanofi projecting a 1.5 percent quarterly earnings per share growth and is betting that a weak euro could help push up its profits.
Sanofi has endured protracted heckling from market watchers, who have watched with bemusement as more than three potential candidates have turned down the top job at the company, after the board ousted former popular Viehbacher in a power struggle over strategy.
Indeed, Wall Street is already speculating that Sanofi‘s Chairman Serge Weinberg may have to publicly acknowledge in his earnings results next week that the company has met with unparalleled difficulty of tempting someone into their head job.
Weinberg has previously declined to comment on rumors that Smith & Nephew French chief Olivier Bohuon, Christophe Weber, the French chief operating officer of Takeda Pharmaceuticals , and AstraZeneca PLC ’s Pascal Soriot had turned down the CEO job at Sanofi.
We have no comment on the subject,” Weinberg said, because he was only speaking “in general” about the difficulty of finding top talent for the position.
A source told Reuters that in the meantime, Sanofi continues to miss out.
“I think it is going to take time,” said a source close to the company told the news service Friday. “What we risk missing in the meantime is a strategic vision that you cannot have without a deep knowledge of the pharmaceuticals sector.”
In the past, Weinberg has complained that the high tax burden imposed upon companies by the French government is hindering Sanofi’s search for a new chief executive.
“The deterioration of French tax-competitiveness and the burden on companies and individuals pose a problem,” Weinberg told reporters in Paris.
“It’s extremely difficult to attract international executives or even bring back French ones who have left. There will be consequences if this continues, because we can’t rely on patriotic sentiment or goodwill alone.”
The situation is likely an ironic one for Weinberg, who was instrumental in ousting Sanofi’s last CEO, Christian Viehbacher, only to find that candidates for the position seem to be thin on the ground. In the interim, Weinberg must fill the role himself, in addition to his duties as chairman.
“The trouble with finding a successor hinges on the fact that we don’t know the real reason he was fired, and because a lot of people are asking themselves questions about the subject,” said an industry insider who has spoken to some potential candidates.
“The very low pay-off he received only reinforces the idea that the reasons he was fired are not the ones that have been talked about.”
Sanofi’s board of directors fired Viehbacher on Oct. 29 because of “strategic differences,” including Viehbacher’s plan to sell the company’s portfolio of mature drugs worth about $7.9 billion.
Although Viehbacher was popular with shareholders because he managed to double the firm’s stock price during his tenure, management had long been at odds with him, particularly because he was the first non-French Sanofi chief executive. When he moves his family to Boston last year, spending only about a third of his time in France, the board acted to remove him.
BioSpace Temperature Poll
Who Do You Think Will Be Sanofi’s New CEO? French drugmaker Sanofi said Thursday that it will name a new chief executive in mere weeks, as it attempted to put to rest rumors that the company could not find any executives willing to take the reins after it unceremoniously ousted its previous CEO last fall. Who do you think will soon be crowned king? BioSpace wants your opinion!
